Type: Securities Fraud case filed

According to the Complaint, the Company made false and misleading statements to the market. Li-Cycle’s Rochester Hub suffered from increasing construction costs. The Company’s so-called “escalating construction costs” were beyond the expected aggregate cost of the project. The Company was forced to halt construction and reevaluate its construction strategy. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Li-Cycle, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. FMC suffered from increased competition from generics following legal defeats in multiple countries. The Company misled investors about its legal struggles and claimed it would not face competition from generics until 2026 or later. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about FMC, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. SCYNEXIS’ ibrexafungerp was manufactured on equipment used to manufacture another substance, creating a risk of cross-contamination. The Company failed to maintain appropriate internal controls and oversight over vendors to ensure current Good Manufacturing Practices (cGMP) were followed. Due to the cross-contamination risk, the Company was forced to place a hold on the clinical trials of ibrexafungerp. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about SCYNEXIS, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Holley’s relationship with resellers and distributors suffered damage due to its extensive focus on its direct-to-consumer (“DTC”) channel. The Company offered discounts to grow the DTC channel, further damaging its important relationships with distributors and resellers. These strained relationships resulting in lower orders, higher returns, and resellers ordering products from the Company’s competitors. Growth in the Company’s DTC channel could not offset the decreased revenues from its historically strong dealer network. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Holley, investor suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. SolarEdge’s European distribution channels carried high inventory levels. These inventory levels resulted in the Company suffering from cancellations and orders being pushed out. The Company overstated its backlog and sales guidance. Based on these facts, the Company’s pubic statements were false and materially misleading throughout the class period. When the market learned the truth about SolarEdge, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Outlook lacked evidence that its lead product candidate, ONS-5010, was a viable treatment for wet age-related macular degeneration (“wet AMD”). The Company and/or its partners lacked sufficient chemistry manufacturing and controls (“CMC”), including problems that were not yet resolved when it resubmitted its BLA to the FDA. The FDA was unlikely to approve the BLA based on this resubmission. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Outlook, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Barclays CEO Jes Staley maintained a close personal relationship with notorious criminal Jeffrey Epstein despite his public assertions to the contrary. Staley was allegedly aware of Epstein’s crimes and allegedly sexually assaulted an Epstein trafficking victim. The Company’s responses to the FCA inquiry into Staley’s relationship with Epstein was false. The Company also failed to update its responses to the FCA inquiry when it knew the answers it submitted were false. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Barclays, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Virtu maintained a generic username and password that allowed its employees including proprietary traders to access the confidential trading information of customers. In fact, the Company enabled its employees to inappropriately access this sensitive customer data by increasing the number of users who could access the database simultaneously. The Company failed to stop its customer’s trading data from being abused. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Virtu, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Brainstorm downplayed the severity of the FDA refusal to file letter. The Company concealed risks associated with its submission of a biologics license application (“BLA”). Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about BrainStorm, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. DocGo failed to maintain an appropriate executive hiring process that could properly vet candidates’ professional and academic backgrounds. This failure increased the chance the Company would suffer from excessive turnover. The Company overstated the effectiveness of its mobile health and transportation services. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about DocGo, investors suffered damages.